Finward Bancorp has entered into a definitive agreement to be acquired by First Financial Bancorp in an all-stock transaction valued at approximately $208 million, with each Finward share converting into 1.35 shares of First Financial common stock.
GoHealth emerged from its prepackaged Chapter 11 bankruptcy on July 21, 2026, converting into a private limited liability company controlled by former first-lien lenders, while existing Class A and Class B common stock was cancelled.
Adapti, Inc. concluded that its 2025 acquisition of Ballengee Group was incorrectly accounted for and that Ballengee Group should have been treated as the accounting acquirer, rendering the company's quarterly financials for the periods ended September 30 and December 31, 2025 unreliable.
Alternus Clean Energy reported no revenue and a net loss for the first quarter of 2026, while its auditor reiterated substantial doubt about the company’s ability to continue as a going concern.
Drugs Made In America Acquisition Corp. filed an 8-K detailing a third amendment to its merger agreement with Power Analytics Global Corp., which restructures founder share treatment, introduces a rights tender offer, resets minimum cash requirements, and pre-approves a potential three-party combination.
Greenidge Generation Holdings, now renamed Vulcan Infrastructure and Power, has entered into agreements for a $39.4 million private investment that will reshape its board, retire most of its senior notes, and accelerate its strategic shift from bitcoin mining to power and digital infrastructure for AI and high-performance computing.
Sangamo Therapeutics disclosed that Nasdaq denied its appeal to remain listed, and the bankruptcy court approved bidding procedures for the sale of the company's assets, setting an August 4 bid deadline and an August 20 sale hearing.
Clover Health reported that a threat actor gained access to three employee accounts through social engineering, potentially exposing member personal and health information.
Ennis, Inc. disclosed that director Michael D. Magill failed to receive a majority of votes at its annual meeting, but the board rejected his tendered resignation after determining that a proxy advisor's recommendation against him was based on incorrect information about his independence.
EyePoint will pay $4.7 million to resolve federal and state allegations that it paid kickbacks to ambulatory surgery centers to induce purchases of its post-cataract surgery drug DEXYCU, and has entered a five-year corporate integrity agreement with the HHS Office of Inspector General.
Record Alpha uses automated systems to identify and summarize public filings, court records, and regulatory actions as they become available. Every article links directly to the primary source document so readers can verify details firsthand. This content is for informational purposes only and is not investment, legal, or financial advice. Full disclaimer →
© 2026 Record Alpha. All rights reserved.